《新股消息》京東健康(06618.HK)孖展額增至近1,100億元 超購逾80倍
京東健康(06618.HK)次日招股,截至下午約6時,本地券商為其借出近1,100億元孖展額,以公開發售部分集資約13.47億元計算,超額認購約80.5倍。
京東健康的招股期將於下周二(12月1日)結束,預期12月8日掛牌上市。今日有市場消息指,由於認購反應熱烈,國際配售部分將提早在下周一(30日)下午5時截止認購。
另外,華潤置地(01109.HK)旗下華潤萬象生活(01209.HK)招股期踏入第三天,券商數據顯示暫錄孖展認購約27億元,以其公開發售部分集資6.13億元計超購近3.5倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.